Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Basel Medical Group appoints Neo Chun How Alton as interim CFO
The Basel Medical Group has appointed Neo Chun How Alton as interim CFO with effect from Monday. He succeeds Jianing Lu, who resigned as chief financial officer. Neo brings experience in corporate finance, restructuring, forensic accounting and tax policy, and was most recently deputy CEO of InCorp Global and worked as a part-time lecturer. » Plus sur de.investing.com
Basel Medical Group remedies NASDAQ violation after filing amended 20-F
Basel Medical Group reports that the noncompliance with periodic reporting obligations was cured after filing the amended annual report on Form 20-F with the SEC on March 13, 2026, and that it meets NASDAQ rule 5250(c)(1). The stock rose nearly 16% last week to $0.69 but is down 83% year-to-date. The company reports more cash than debt, has a market capitalization of $12.96 million and operates clinical sites in Singapore. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | décembre 2025 | |
|---|---|---|
| Chiffre d'affaires | 5,46 M | - |
| Bénéfice brut | -651,38 k | - |
| Bénéfice net | 177,82 k | - |
| EBITDA | -570,09 k | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 6,65 M € |
Nombre d'actions | 1,57 M |
Plus haut/bas sur 52 semaines | 22,20 € - 3,59 € |
| Dividendes | Non |
Bêta | 0,26 |
Ratio P/E | -17,90 |
Ratio PEG | -0,18 |
Ratio P/B | 1,56 |
Ratio P/S | 0,69 |
Profil de l'entreprise
| Nom | BASEL MED GROUP LTD. O.N. |
| PDG | Yen Feng Chhoa |
| Employés | 82 |
Découvrir des actifs
Les actionnaires de BASEL MED GROUP LTD. O.N. investissent également dans les actifs suivants
